NY-THE-ROHATYN-GROUP
6.1.2022 13:32:06 CET | Business Wire | Press release
The Rohatyn Group (“TRG”), an asset management firm with expertise in emerging markets and real assets, announced today that it is appointing Colin Clark and Erik Kankainen as Partners. Mr. Clark, who is based in London, leads TRG’s private equity investments in Europe across a wide range of sectors. Mr. Kankainen, who is based in Boston, is responsible for the management and financial analysis of TRG’s Northern Hemisphere timber and agriculture investments. Mr. Clark and Mr. Kankainen joined the firm following the acquisitions of Citi Venture Capital International (CVCI) in 2013 and GMO Renewable Resources (GMORR) in 2017, respectively.
TRG Partner and Head of Private Markets Miguel Gutierrez said: “The addition of Colin reflects our expectation that the CEE region, along with broader peripheral Europe, offers highly compelling investment opportunities and will continue to do so in the years to come. Colin has vast experience with complex transactions, and developed and implemented a pioneering East to West European private equity strategy.”
TRG Partner and Head of Forestry and Agriculture Mike Claridge said: “Erik’s unparalleled experience in and knowledge of the timber sector has been instrumental in growing TRG’s forestry and agriculture practice. Erik has helped build out a rigorous investment management model well suited to the rapidly changing landscape for the forestry asset class.”
TRG CEO Nick Rohatyn added: “Erik and Colin both exemplify TRG’s collaborative, entrepreneurial, and determined culture. Their unique experiences contribute highly complementary perspectives and skillsets to the TRG partnership, and we are proud to recognize their hard work and talent.”
Mr. Clark has over 20 years of private equity experience in Europe spanning buy-outs and growth capital investments. He currently serves on the Amethyst Radiotherapy, Optimapharm, Prestige and Tallink Boards of Directors. Prior to joining TRG in December 2013, Mr. Clark was a Partner at CVCI and a member of the investment team from 2003. Before CVCI, Mr. Clark originated and structured project finance transactions for Citi across the EMEA region. From 1996 to 2000, he worked with Bank of Scotland in Edinburgh in various positions in project finance and acquisition finance.
Mr. Kankainen has over 15 years of experience in timber investing. Prior to its acquisition by TRG in December 2017, Mr. Kankainen was a forest investment manager for GMORR. Before joining GMORR in 2012, he was a Senior Economist in Bioenergy at Forest Economic Advisors and a Senior Analyst in Timber at RISI, Inc.
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets headquartered in New York, with a global presence in 18 cities across the US, Latin America, Europe, the Middle East, India and Southeast Asia. For more information, please visit www.rohatyngroup.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom